Lck SH2 inhibitors (KRICT)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameLck SH2 inhibitors (KRICT)
Drug Alias Namelymphocyte-specific protein tyrosine kinase SH2 inhibitors (KRICT)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase LCK inhibitors
TargetsTyrosine-protein kinase LCK
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKorea Research Institute Of Chemical Technology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKorea Research Institute Of Chemical Technology
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A